EUS 2008 Working Group document: evaluation of EUS-guided injection therapy for tumors

Gastrointestinal Endoscopy

Volumn 69, Issue 2 SUPPL., 2009, Pages

  Chang, Kenneth J ^a   Irisawa, Atsusi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; EARLY GROWTH RESPONSE FACTOR 1; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC HERPES VIRUS; ONYX 015; PHOSPHORUS 32; TNFERADE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; BRACHYTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; CONTINUOUS INFUSION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM PERFORATION; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FATIGUE; FEVER; GENE TRANSFER; HUMAN; IMPLANT; LYMPHOCYTE CULTURE; NAUSEA; NEEDLE; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR SEEDING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ENDOSONOGRAPHY; HUMANS; INJECTIONS, INTRALESIONAL; NEOPLASMS;

EID: 58849159280     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2008.10.057     Document Type: Article

References (20)

1. Hochster H.S., Haller D.G., de Gramont A., et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107 (2006) 676-685
2. Moore M.J. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32 Suppl 8 (2005) 5-6
3. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13 (2006) 1035-1046
4. Firusian N., and Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 85 (1999) 980-987
5. Order S.E., Siegel J.A., Principato R., et al. Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study. Int J Radiat Oncol Biol Phys 36 (1996) 1117-1126
6. Rosemurgy A., Luzardo G., Cooper J., et al. 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. J Gastrointest Surg 12 (2008) 682-688
7. Mulvihill S., Warren R., Venook A., et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8 (2001) 308-315
8. Heise C.C., Williams A., Olesch J., et al. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 6 (1999) 499-504
9. Micames C., Jowell P.S., White R., et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58 (2003) 690-695
10. Chang K.J. Endoscopic ultrasound-guided fine needle aspiration in the diagnosis and staging of pancreatic tumors. Gastrointest Endosc Clin N Am 5 (1995) 723-734
11. Chang K.J., Nguyen P.T., Thompson J.A., et al. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer 88 (2000) 1325-1335
12. Hecht J.R., Bedford R., Abbruzzese J.L., et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9 (2003) 555-561
13. Chang K.J., Senzer N., Chung T., et al. A novel gene transfer therapy against pancreatic cancer (TNFerade) delivered by endoscopic ultrasound (EUS) and percutaneous guided fine needle injection (FNI). [abstract]. Gastrointest Endosc 59 (2004) 188
14. Farrell J.J., Senzer N., Hecht J.R., et al. Long-term data for endoscopic ultrasound (EUS) and percutaneous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). [abstract]. Gastrointest Endosc 63 (2006) AB93
15. Chang K.J., Lee J.G., Holcombe R.F., et al. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 107-111
16. Mundt A.J., Vijayakumar S., Nemunaitis J., et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10 (2004) 5747-5753
17. McLoughlin J.M., McCarty T.M., Cunningham C., et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 12 (2005) 825-830
18. Chang K.J., Senzer N., Swisher S., et al. Multi-center clinical trial using endoscopy and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of anti-tumor agent (TNFerade™) in patients with locally advanced esophageal cancer. [abstract]. Gastrointest Endosc 63 (2006) AB84
19. Irisawa A., Takagi T., Kanazawa M., et al. Endoscopic ultrasound-guided fine-needle injection of immature dendritic cells into advanced pancreatic cancer refractory to gemcitabine: a pilot study. Pancreas 35 (2007) 189-190
20. Kasuya H., Takeda S., Nomoto S., et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12 (2005) 725-736